| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 09/02/2004 | US20040171802 Haemophilus influenzae antigens and corresponding dna fragments |
| 09/02/2004 | US20040171796 comprising an agonist of a majort histocompatability complex (MHC) class I binding native sequence having enhanced immunogenicity; for inhibiting or killing CEA epitope-expressing carcinoma cells; genetic engineering; kits |
| 09/02/2004 | US20040171569 that directs formation of a recombinant virus upon introduction into a cell |
| 09/02/2004 | US20040171565 vaccines that express derivatives of ADP-ribosyltransferase toxins that display significantly reduced, or are deficient in, intrinsic ADP-ribosyltransferase activity (i.e. herein referred to as mARTs) and yet retain adjuvanticity |
| 09/02/2004 | US20040171552 for treating a condition involving abnormal cell migration in a subject |
| 09/02/2004 | US20040171539 Regulation of human protein kinase-like protein |
| 09/02/2004 | US20040171523 Immunogenic glycopeptides, screening, preparation and uses |
| 09/02/2004 | US20040171150 Antisense nucleotide sequences for prevention and treatment of sepsis, viral infection, autoimmune and cell proliferative disorders |
| 09/02/2004 | US20040171132 Comprises nucleotide sequences coding herpes virus glycoprotein for developing vaccine which prevents respiratory system disorders in poulty; veterinary medicine; genetic vaccines |
| 09/02/2004 | US20040171123 fusion protein of an antibody that binds to human epidermal growth factor receptor-2 (HER2) and albumin with long shelf-life; stabilizing therapeutic proteins such as antibodies by conjugating them to albumin |
| 09/02/2004 | US20040171121 Methods for preparing Bacillus anthracis sporulation deficient mutants and for producing recombinant Bacillus anthracis protective antigen for use in vaccines |
| 09/02/2004 | US20040171117 Anti-RANK ligand monoclonal antibodies useful in treatment of RANK ligand mediated disorders |
| 09/02/2004 | US20040171113 Antigens of group b streptococcus and corresponding dna fragments |
| 09/02/2004 | US20040171111 Polypeptide of a p53 protein-specific murin a/t-cell receptor, nucleic acids coding therefor and use thereof |
| 09/02/2004 | US20040171090 Screening for cytotoxic t-lymphocyte recognition antigen associated with human t-cell leukemia virus infected cells for diagnosing and prognosing inflammation and cell proliferation disorders |
| 09/02/2004 | US20040171081 Identifying immunodominant epitope for elliciting immune response to treat and prevent tumors and infections; immunotherapy |
| 09/02/2004 | US20040171020 Glanders/meliodosis vaccines |
| 09/02/2004 | US20040170999 Nuclear hormone receptor ligand binding domain |
| 09/02/2004 | US20040170982 Novel therapeutic targets in cancer |
| 09/02/2004 | US20040170972 comprises DNA vaccine, a recombinant vaccine, and a T cell epitope vaccine; includes use of serological diagnosis; genetic engineering |
| 09/02/2004 | US20040170961 for drug screening anticancer agents; solid phase synthesis; animal models; genetic engineering; kits |
| 09/02/2004 | US20040170960 Lectin compositions and methods for modulating an immune response to an antigen |
| 09/02/2004 | US20040170951 Nucleotide sequences of the nucleocapsid (NP) and phosphoprotein (P) genes of a malaysian velogenic newcastle disease virus strain AF2240 and the production of the NP and P proteins in Escherichia coli |
| 09/02/2004 | US20040170694 Therapeutic and prophylactic compositions including catalytic biomimetic solids and methods to prepare and use them |
| 09/02/2004 | US20040170653 recognised by CD8-positive cytotoxic T-lymphocytes as a peptide antigen and causes a CTL-induced lysis and/or apoptosis of tumor or leukemia cell; has the amino acid sequence LLGDLFGV, which corresponds to the amino acid positions 81 to 88 of the hdm2 proto-oncoprotein |
| 09/02/2004 | US20040170652 Saponin inactivated mycoplasma vaccine |
| 09/02/2004 | US20040170649 uses optimal solvent systems such that the lipid envelope around the viral particle is dissolved while the viral particle remains intact; autologous vaccines |
| 09/02/2004 | US20040170648 first valence adjuvanted with an aluminum hydroxide (especially Hepatite A); second valence contains a bacterial capsule polysaccharide with O-acetyl groups (especially typhoid fever valence formed by the polysaccharide Vi of the Salmonella typhi capsule); and phosphate, citrate or carbonate ions. |
| 09/02/2004 | US20040170647 Recombinant adenovirus vaccines |
| 09/02/2004 | US20040170646 Preferred are EB1 or EB14 cell; canary poxvirus containins a exogenous DNA sequence that encodes a tumor antigen, an antigen derived from a human pathogen, or a fragment thereof; vaccines |
| 09/02/2004 | US20040170644 Mixture of peptides derived from e6 and/or e7 papillomavirus proteins and uses thereof |
| 09/02/2004 | US20040170643 heat shock protein fused to a single epitope-containing segment comprising two or more identical epitopes and a DNA construct encoding it; reducing levels of a predetermined protein (e.g., hormone(s)) in an animal; vaccines |
| 09/02/2004 | US20040170642 Vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide of a derivative thereof |
| 09/02/2004 | US20040170641 Prevention and treatment of amyloidogenic disease |
| 09/02/2004 | US20040170640 Methods for preparing and delivering adjuvant compositions |
| 09/02/2004 | US20040170639 administering by whole body spray a live avirulent derivative of an enteropathogenic bacterium that contains a recombinant gene encoding the protein, other than one that causes respiratory disease in birds; vaccines |
| 09/02/2004 | US20040170637 Use of rmLT as a marker antigen for vaccines and as a synergistic adjuvant with AMPHIGEN |
| 09/02/2004 | US20040170636 DNA vaccine comprising a plasmid vector encoding the A2 gene from Leishmania donovani; vector may also encode a gene, such as the Human papillomavirus E6 gene, capable of mediating degradation of the cellular protein p53, to inhibit the p53 response |
| 09/02/2004 | US20040170635 administering an inhibitor of the CD2/LFA-3 interaction, in combination with narrow band UVB radiation; especially for treating psoriasis |
| 09/02/2004 | US20040170633 Enhancing the efficacy of immunotherapies by supplementing with complement |
| 09/02/2004 | US20040170632 Liquid formulation comprising cetuximab and a fatty acid ester of polyoxyethylene sorbitan |
| 09/02/2004 | US20040170627 Antagonists of Myelin-associated Glycoprotein and their use in the treatment and/or prevention of Neurological diseases |
| 09/02/2004 | US20040170624 active principle, especially the humanized monoclonal antibody JAQ1, that induces irreversible inactivation or degradation of the collagen receptor on thrombocytes; diagnostic agent for the determination of the expression rate of the collagen receptor GPVI |
| 09/02/2004 | US20040170623 having a concentration of at least 50 mg/ml of the antibody and containing an acidic component; nasal sprays and slow release formulations drying or freeze-drying |
| 09/02/2004 | US20040170622 Methods and compositions for modulating XBP-1 activity |
| 09/02/2004 | US20040170620 Selected antibody compositions for binding to aminophospholipids |
| 09/02/2004 | US20040170611 culturing an autologous or allogenic dermal papilla cell in the presence of a Wnt polypeptide or a fragment or analog thereof, and grafting the cultured cell onto the skin |
| 09/02/2004 | US20040170603 Using radiolabeled annexin; radiotherapy for tumors |
| 09/02/2004 | CA2787820A1 Glycoprotein antigen sima135 expressed in metastatic human tumor cells |
| 09/02/2004 | CA2517006A1 Methods for the treatment and prevention of diseases of biological conduits |
| 09/02/2004 | CA2516971A1 Secreted chlamydia polypeptides, polynucleotides coding therefor, therapeutic and diagnostic uses thereof |
| 09/02/2004 | CA2516454A1 Methods for treating pain by administering a nerve growth factor antagonist and an nsaid and compositions containing the same |
| 09/02/2004 | CA2516320A1 Induced activation in dendritic cells |
| 09/02/2004 | CA2516138A1 Therapeutic gpcr targets in cancer |
| 09/02/2004 | CA2516128A1 Therapeutic targets in cancer |
| 09/02/2004 | CA2515978A1 Vaccination or immunization using a prime-boost regimen against bhv-1 |
| 09/02/2004 | CA2515965A1 Inhibition of tace or amphiregulin for the modulation of egf receptor signal transactivation |
| 09/02/2004 | CA2515779A1 Contraceptive method and compositions related to proteasomal interference |
| 09/02/2004 | CA2515398A1 Idiotypic vaccine |
| 09/02/2004 | CA2514979A1 Antibody vaccine conjugates and uses therefor |
| 09/02/2004 | CA2514485A1 Compositions comprising fetal hemoglobin and bacterial endotoxin and optionally additional fetal liver components |
| 09/02/2004 | CA2514277A1 Methods and compositions for administering therapeutic and diagnostic agents |
| 09/02/2004 | CA2512930A1 Inactivated nodavirus vaccine |
| 09/02/2004 | CA2498650A1 Mycobacterial diagnostics |
| 09/01/2004 | EP1452542A2 Reshaped human monoclonal antibodies specific for IgE |
| 09/01/2004 | EP1452541A1 Hepatitis e virus monoclonal antibodies or the binding fragments of it and the use thereof |
| 09/01/2004 | EP1451590A2 Peptides and method for detecting alzheimer's disease and differentiating alzheimer's disease from other demential diseases |
| 09/01/2004 | EP1451578A2 Composition comprising and method of using angiopoietin-like protein 3 angptl3 |
| 09/01/2004 | EP1451552A2 Reagents and methods useful for detecting diseases of the breast |
| 09/01/2004 | EP1451369A2 Methods and compositions to treat cardiovascular disease usin g 1419, 58765 and 2201 |
| 09/01/2004 | EP1451364A2 Methods and compositions for treating hematological disorders using 232, 2059, 10630, 12848, 13875, 14395, 14618, 17692 or 58874 |
| 09/01/2004 | EP1451338A1 Recombinant antibodies for the detection and neutralization of anthrax toxin |
| 09/01/2004 | EP1451337A2 Nogo receptor-mediated blockade of axonal growth |
| 09/01/2004 | EP1451333A2 Ul16 binding protein 4 |
| 09/01/2004 | EP1451329A2 Genetic vaccine against human immunodeficiency virus |
| 09/01/2004 | EP1451324A2 G-protein coupled receptor lustr2 and uses thereof |
| 09/01/2004 | EP1451307A2 Type 2 cytokine receptor and nucleic acids encoding same |
| 09/01/2004 | EP1451305A2 Epitope synchronization in antigen presenting cells |
| 09/01/2004 | EP1451226A1 Antigen presenting cell targeting conjugate, an antigen presenting cell contacted with such conjugate, their use for vaccination or as medicament, and methods for their production or generation |
| 09/01/2004 | EP1451222A2 Novel proteins with il-6 inhibiting activity |
| 09/01/2004 | EP1451221A2 GIPs, A FAMILY OF POLYPEPTIDES WITH TRANSCRIPTION FACTOR ACTIVITY THAT INTERACT WITH GOODPASTURE ANTIGEN BINDING PROTEIN |
| 09/01/2004 | EP1451220A2 Peptides for the production of preparations for the diagnosis and therapy of autoimmun diseases |
| 09/01/2004 | EP1451216A1 Immunointeractive molecules and uses thereof |
| 09/01/2004 | EP1450862A1 Replication competent dual-ad vectors for vaccine and immunotherapy applications |
| 09/01/2004 | EP1450859A2 Methods and compositions for the diagnosis of asthma |
| 09/01/2004 | EP1450858A2 Methods for treating cancer using a combination of a tumor-derived dendritic cell inhibitory factor antagonist and a toll-like receptor agonist |
| 09/01/2004 | EP1450857A2 Broadly cross-reactive neutralizing antibodies against human immunodeficiency virus selected by env-cd4-co-receptor complexes |
| 09/01/2004 | EP1450856A2 Packaging of immunostimulatory substances into virus-like particles: method of preparation and use |
| 09/01/2004 | EP1450855A2 Suppression of allergic reactions by transdermal administration of allergens in conjunction with or conjugated to toxin subunits or fragments thereof |
| 09/01/2004 | EP1450854A2 Vaccine |
| 09/01/2004 | EP1450844A2 Polymeric thiol-linked prodrugs employing benzyl elimination systems |
| 09/01/2004 | EP1450839A2 Method of treating estrogen responsive breast cancer |
| 09/01/2004 | EP1450830A2 Minor histocompatibility antigen ha-1: target antigen for immunotherapy of tumors |
| 09/01/2004 | EP1450828A2 In situ immunization |
| 09/01/2004 | EP1450821A1 Immunostimulatory oligodeoxynucleotides |
| 09/01/2004 | EP1450752A2 Multivalent streptococcal vaccine compositions and methods for use |
| 09/01/2004 | EP1450610A2 Probiotic compositions |
| 09/01/2004 | EP1220659B1 Pharmaceutical products and methods of fabrication therefor |
| 09/01/2004 | EP1024824B1 Solid dispersing vaccine composition for oral delivery |
| 09/01/2004 | EP1014787B1 Adjuvant for transcutaneous immunization |